Results 101 to 110 of about 57,506,680 (308)

Unique circulating miRNAome signatures captured with distinct molecular states in Lynch syndrome and sporadic colorectal cancer

Molecular Oncology, EarlyView.
Circulating microRNA profiles distinguish nonmalignant Lynch syndrome from cancer‐associated Lynch syndrome, sporadic colorectal cancer, and healthy controls. Age‐stratified analysis reveals disease‐specific regulatory states, and a six‐miRNA panel shows concordant separation in an independent colorectal tissue cohort.
Ramadhani Salum Chambuso, Md Shohel Ul Islam, Rosa M Xicola, Raj Ramesar, Xavier Llor, Sinclair Steele   +5 more
wiley   +1 more source

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

Molecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim, Alvin Kunyao Guo, Yoko Itahana, Srinivasaraghavan Kannan, Valerie Goh, Mingmin Ong, Terina Yan Wen Tay, Weiying Ye, Sabhashina Radha Krishnan, Jun Nishiyama, Chandra S Verma, Koji Itahana   +11 more
wiley   +1 more source

Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in acute lung injury to reduce pulmonary dysfunction (HARP-2) trial : study protocol for a randomized controlled trial [PDF]

, 2012
Acute lung injury (ALI) is a common devastating clinical syndrome characterized by life-threatening respiratory failure requiring mechanical ventilation and multiple organ failure.
O'Kane, Cecilia M., O’Kane, Cecilia M., Laffey, John G, Cross, Mark, John G Laffey, McAuley, Daniel F; id_orcid, McNally, Christine, Michael Stevenson, Perkins, Gavin D., Crealey, Grainne, Laffey, John G., Daniel F McAuley, Murphy, Lynn, HASH(0x55a67ff73468), Stevenson, Michael, Cross, L. J. Mark, Grainne Crealey, Cecilia M O’Kane, McAuley, Daniel F., Mark Cross, null null, Gavin D Perkins, Perkins, Gavin D, Christine McNally, Lynn Murphy, O'Kane, Cecilia M, Cross Mark, Stevenson Michael, Murphy Lynn, McNally Christine, Crealey Grainne, Laffey John G, O’Kane Cecilia M, McAuley Daniel F, Perkins Gavin D, McAuley, Daniel F, and the HARP-2 investigators on behalf of the Irish Critical Care Trials Group, O’Kane, Cecilia M   +37 more
core   +2 more sources

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source

Questions asked and answered in pilot and feasibility randomized controlled trials [PDF]

, 2011
Background In the last decade several authors have reviewed the features of pilot and feasibility studies and advised on the issues that should be addressed within them.
Shanyinde Milensu, Weatherall, M., Mark Weatherall, Ruth M Pickering, Pickering, R.M., Shanyinde, M., Pickering Ruth M, Weatherall Mark, Milensu Shanyinde   +8 more
core   +2 more sources

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

Molecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir, Elena Haro‐Martínez, Sandra Blasco‐Benito, Chiara Cannatà, José Ángel Palomeque, Anna López‐Plana, Maria Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià‐Terrassa   +9 more
wiley   +1 more source

Cluster randomized trial in the general practice research database: 2. Secondary prevention after first stroke (eCRT study): study protocol for a randomized controlled trial. [PDF]

, 2012
BACKGROUND: The purpose of this research is to develop and evaluate methods for conducting pragmatic cluster randomized trials in a primary care electronic database.
Wolfe Charles, Van Staa, Tjeerd; id_orcid, van Staa, Tjeerd, Mcdermott Lisa, Judith Charlton, Gulliford, Martin, Gerard McCann, Charlton, Judith, Ashworth Mark, Ashworth, Mark, Dregan Alex, McCann, Gerard, Charlton Judith, Anthony Rudd, Rudd Anthony, Lucy Yardley, Mark Ashworth, Gulliford Martin, Dregan, Alex; id_orcid, McCann Gerard, Lisa Mcdermott, Martin Gulliford, Tjeerd van Staa, Dregan, Alex, Yardley, Lucy, ?, ?, McDermott, Lisa, van Staa Tjeerd, null null, Wolfe, Charles, Yardley Lucy, Rudd, Anthony, eCRT Research Team, Charles Wolfe, Alex Dregan   +34 more
core   +2 more sources

Characteristics of included randomized controlled trials.

, 2023
Characteristics of included randomized controlled trials.
Yang Hai (830201), Haidong Deng (8128269), Fang Fang (38179), Jialing He (2339845), Yi Yang (116183), Tiangui Li (4909354), Peng Wang (34436), Yixin Tian (384345), Xin Cheng (179584), Yuning Feng (15389183), Yu Zhang (12946), Yangchun Xiao (13559293), Weelic Chong (9235617)   +12 more
core   +1 more source

Tumour‐proximal deep serum proteomics identifies biomarkers associated with ovarian cancer

Molecular Oncology, EarlyView.
New biomarkers are needed for early ovarian cancer detection. Ovarian (tumour‐proximal) and peripheral vein serum from healthy women and patients with benign or malignant tumours underwent nanoparticle‐enriched deep proteomics. Ovarian serum yielded more protein identifications and revealed tumour‐reflective signatures.
Darren Lau, Daniel Pincher, Clifford Young, Nicholas Chappell, Noor A. Lokman, Parul Mittal, Leigh Donnellan, Martin K. Oehler, Doug A. Brooks, Peter Hoffmann   +9 more
wiley   +1 more source